Here we reported preclinical data for iruplinalkib, a novel ATP-competitive ALK/ROS1 inhibitor, the efficacy and safety of which were currently evaluated in patients who have not been treated with ALK-positive NSCLC in a phase III clinical trial (NCT04632758). This evidence concerns the gene ALK and non-small cell lung carcinoma.